http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9360487-B2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7fb0b2ec1c62686bd1f63f161596afee |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-70567 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-7028 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-47 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-743 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57415 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6848 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-74 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
| filingDate | 2014-03-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2016-06-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b9136e6a7847dc58ba5a6bbc0b940ce7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3fbee97e83ab572e81eb31eaf2614c15 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4cf4efa652fead182f929d0c6a2d9fe4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_31ecdfe678279b1a8e56af827e77edcc |
| publicationDate | 2016-06-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-9360487-B2 |
| titleOfInvention | Multiplex MRM assay for evaluation of cancer |
| abstract | The current disclosure provides specific peptides, and derived ionization characteristics of the peptides from the estrogen receptor (ER), progesterone receptor (PR), and/or antigen Ki67 (Ki67) proteins that are particularly advantageous for quantifying the ER, PR, and/or Ki67 proteins directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring/Multiple Reaction Monitoring (SRM/MRM) mass spectrometry. Such biological samples are chemically preserved and fixed wherein the biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded. A protein sample is prepared from a biological sample using the Liquid Tissue™ reagents and protocol, and the ER, PR, and/or Ki67 proteins are quantitated in the Liquid Tissue™ sample by the method of SRM/MRM mass spectrometry by quantitating in the protein sample at least one or more of the peptides described for one or more of the ER, PR, and/or Ki67 proteins. These peptides can be quantitated if they reside in a modified or in an unmodified form. An example of a modified form of an ER, PR, and/or Ki67 peptide is phosphorylation of a tyrosine, threonine, serine, and/or other amino acid residues within the peptide sequence. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2019033320-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2018172690-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10725051-B2 |
| priorityDate | 2011-09-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 43.